2018
DOI: 10.1111/1753-0407.12788
|View full text |Cite
|
Sign up to set email alerts
|

Myocardial considerations in type 2 diabetes: 2018

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 29 publications
0
1
0
Order By: Relevance
“…Richard Pratley describes some of the important cardiovascular safety trials of novel therapeutic agents for diabetes, which suggest that certain approaches may convey specific cardiovascular outcome benefits . Finally, Robert Chilton and Mark Kearney, in two contributions, discuss an aspect of cardiovascular disease that has increasingly been seen as important in insulin‐resistant states: congestive heart failure. New understandings and treatments of congestive heart failure have emerged as analysis of the safety trials has proceeded.…”
mentioning
confidence: 99%
“…Richard Pratley describes some of the important cardiovascular safety trials of novel therapeutic agents for diabetes, which suggest that certain approaches may convey specific cardiovascular outcome benefits . Finally, Robert Chilton and Mark Kearney, in two contributions, discuss an aspect of cardiovascular disease that has increasingly been seen as important in insulin‐resistant states: congestive heart failure. New understandings and treatments of congestive heart failure have emerged as analysis of the safety trials has proceeded.…”
mentioning
confidence: 99%